Deutsch English Français

Contact

EP1491211

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1491211

EP1491211 - REMEDY FOR GLIOBLASTOMA [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 10.01.2014 Database last updated on 14.09.2024
Most recent event Tooltip	10.01.2014	Application deemed to be withdrawn	published on 12.02.2014 [2014/07]
Applicant(s)	For all designated states Astellas Pharma Inc. 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo / JP
	[N/P]
Former [2005/35]	For all designated states Astellas Pharma Inc. 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo / JP
Former [2005/01]	For all designated states YAMANOUCHI PHARMACEUTICAL CO. LTD. No. 3-11 Nihonbashi-Honcho, 2-chome Chuo-ku Tokyo 103-8411 / JP
Inventor(s)	01 / ISHIUCHI, Shogo 13-7, Furuichi-cho 1-chome Maebashi-shi, Gunma 371-0844 / JP
	[2005/01]
Representative(s)	Bates, Philip Ian Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS / GB
	[N/P]
Former [2005/01]	Bates, Philip Ian Reddie & Grose 16 Theobalds Road London WC1X 8PL / GB
Application number, filing date	03715539.7	27.03.2003
	[2005/01]
	WO2003JP03867
Priority number, date	JP20020094313	29.03.2002 Original published format: JP 2002094313
	[2005/01]
Filing language	JA
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO03082332
	Date:	09.10.2003
	Language:	EN
	[2003/41]
	Type:	A1 Application with search report
	No.:	EP1491211
	Date:	29.12.2004
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 09.10.2003 takes the place of the publication of the European patent application.
	[2004/53]
Search report(s)	International search report - published on:	JP	09.10.2003
	(Supplementary) European search report - dispatched on:	EP	11.12.2009
Classification	IPC:	A61K45/00, A61K31/498, A61K31/542, A61P25/00, A61P35/00, A61P43/00, C07D241/38, C07D403/04, C07D513/04	[2005/01]
	CPC:	A61K31/542 (EP,KR,US); A61K31/498 (EP,KR,US); A61K31/00 (EP,US); A61P25/00 (EP); A61P35/00 (EP); A61P43/00 (EP)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR [2005/01]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
Title	German:	MITTEL ZUR BEHANDLUNG VON GLIOBLASTOM	[2005/01]
	English:	REMEDY FOR GLIOBLASTOMA	[2005/01]
	French:	MEDICAMENT CONTRE LE GLIOBLASTOME	[2005/01]
Entry into regional phase	14.09.2004	Translation filed
	20.09.2004	National basic fee paid
	20.09.2004	Search fee paid
	20.09.2004	Designation fee(s) paid
	20.09.2004	Examination fee paid
Examination procedure	11.07.2003	Request for preliminary examination filed International Preliminary Examining Authority: JP
	20.09.2004	Examination requested [2004/53]
	26.02.2010	Amendment by applicant (claims and/or description)
	12.04.2010	Despatch of a communication from the examining division (Time limit: M06)
	13.10.2010	Reply to a communication from the examining division
	09.04.2013	Communication of intention to grant the patent
	20.08.2013	Application deemed to be withdrawn, date of legal effect [2014/07]
	25.09.2013	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2014/07]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 12.04.2010
Fees paid	Renewal fee
	20.09.2004	Renewal fee patent year 03
	09.03.2006	Renewal fee patent year 04
	14.03.2007	Renewal fee patent year 05
	14.03.2008	Renewal fee patent year 06
	13.03.2009	Renewal fee patent year 07
	15.03.2010	Renewal fee patent year 08
	15.03.2011	Renewal fee patent year 09
	14.03.2012	Renewal fee patent year 10
	11.03.2013	Renewal fee patent year 11
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]WO0024395 (IKONOMIDOU HRISSANTHI [DE]) [X] 1-3,5-7,9-11 * page 7, paragraphs 1-3 * * page 16, paragraphs 1,4-6 * * claims 1,5,9 *;
		[X] - ISHIUCHI ET AL, "A CRUCIAL ROLE OF CA2+-PERMEABLE AMPA RECEPTORS IN HUMAN GLIOBLASTOMA CELLS", JIKKEN IGAKU - EXPERIMENTAL MEDICINE, YODOSHA, TOKYO, JP, (20020101), vol. 20, no. 18, ISSN 0288-5514, pages 2651 - 2653, XP008070096 [X] 1,3,5,7,9,11 * the whole document *
		[DX] - RZESKI W ET AL, "Glutamate antagonists limit tumor growth", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, (20010522), vol. 98, no. 11, ISSN 0027-8424, pages 6372 - 6377, XP002968567 [DX] 1,3,5,7,9,11 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.091113598
		[DY] - LABRAKAKIS C ET AL, "Glutamate receptor activation can trigger electrical activity in human glioma cells.", THE EUROPEAN JOURNAL OF NEUROSCIENCE JUN 1998, (199806), vol. 10, no. 6, ISSN 0953-816X, pages 2153 - 2162, XP002558225 [DY] 1-12 * the whole document * DOI: http://dx.doi.org/10.1046/j.1460-9568.1998.00226.x
		[DY] - ROTHSTEIN J D ET AL, "Excitotoxic destruction facilitates brain tumor growth", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (20010101), vol. 7, no. 9, ISSN 1078-8956, pages 994 - 995, XP002490995 [DY] 1-12 * the whole document * DOI: http://dx.doi.org/10.1038/nm0901-994
		[Y] - ISHIUCHI S ET AL, "Extension of glial processes by activation of Ca2+-permeable AMPA receptor channels", NEUROREPORT, LIPPINCOTT WILLIAMS & WILKINS, US, (20010326), vol. 12, no. 4, ISSN 0959-4965, pages 745 - 748, XP002974830 [Y] 1-12 * the whole document * DOI: http://dx.doi.org/10.1097/00001756-200103260-00026
		[Y] - YE Z-C ET AL, "Glioma cells release excitotoxic concentrations of glutamate", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, (19990901), vol. 59, no. 17, ISSN 0008-5472, pages 4383 - 4391, XP002331150 [Y] 1-12 * the whole document *
	International search	[Y]WO9610023 (YAMANOUCHI PHARMA CO LTD [JP], et al);
		[Y]WO9717970 (YAMANOUCHI PHARMA CO LTD [JP], et al);
		[Y]WO0054772 (AVENTIS PHARMA SA [FR], et al);
		[AP]WO03000928 (ODIN MEDICAL AS [DK], et al);
		[Y] - TAKANO T. ET AL., "Glutamate relkated promotes growth of malignant gliomas", NATURE MEDICINE, (2001), vol. 7, no. 9, pages 1010 - 1015, XP002970005 DOI: http://dx.doi.org/10.1038/nm0901-1010
		[Y] - FLORIAN CATARINA L. ET AL., "Characteristic metabolic profiles reveald by 1H NMR spectroscopy of three types of human brain and nervous system tumours", NMR IN BIOMEDICINE, (1996), vol. 8, pages 253 - 264, XP002970006
		[XP] - ISHIUCHI S. ET AL., "Blockage of Ca2+-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells", NATURE MEDICINE, (200209), vol. 8, no. 9, pages 971 - 978, XP002970007 DOI: http://dx.doi.org/10.1038/nm746

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p